Frisco, TX – According to filings with the U.S. Securities and Exchange Commission, Kwivik Therapeutics is raising $20,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Julian Ross played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Kwivik Therapeutics

Kwivik Therapeutics Inc. is a pre-IPO medtech leader that has developed a novel way to create medical oxygen from two, dry inert powders. The oxygen is created on demand, without the need for pressurized storage. We combined this “oxygen from powder” technology with innovative biotech, engineering, IoT and AI technologies to develop a robust pipeline of novel products to disrupt certain respiratory, emergency medical, asthma, cluster headache/migraine, wound care and skin care markets, with a combined market size exceeding a remarkable $750 Billion. We are a medical technology platform company with three product areas: (A) Therapeutics; (B) Emergency Medical; and (C) Medical Aesthetics. In addition, we plan to fuel our future growth in related areas through continued innovation and by acquisition. All our product applications are enhanced by a pervasive, cloud-based Mobile, Internet of Things (IoT) and Artificial Intelligence (AI) strategy (our Mobile apps, IoT architecture and AI algorithms are all proprietary).

To learn more about Kwivik Therapeutics, visit http://www.kwivikmedical.com/

Contact:
Julian Ross, Chief Executive Officer
972-752-3400
https://www.linkedin.com/in/julian-ross-2b197a14/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved